• No results found

Targeting the genetic code to cure diseases Akif Görgülü

N/A
N/A
Protected

Academic year: 2022

Share "Targeting the genetic code to cure diseases Akif Görgülü"

Copied!
1
0
0

Loading.... (view fulltext now)

Full text

(1)

1

Targeting the genetic code to cure diseases

Akif Görgülü

Popular Science Summary of Independent Project in Biology 2016 Biology Education Centre, Uppsala University

It is small, it is short and it can cure diseases. DNA’s cousin can be used in gene therapy to treat a variety of genetic diseases and cancer, as well as fight against bacterial and viral infections. The cousin, small interfering RNA (siRNA), are so called because of their small size and their natural ability to interfere with protein synthesis. This ability is taken

advantage of to silence bacterial, viral or native pathogenic genes to essentially cure diseases.

RNA

RNA is composed of ribose sugars instead of deoxyribose like DNA, and it is usually single- stranded in contrast to the double-stranded (ds) DNA molecule. RNA is a widely-known molecule as a coding strand for protein synthesis in all forms of life. However, there are other roles of RNA and they too can exist in a double-stranded nature like their cousin, the DNA.

Inhibition of protein synthesis

DsRNA in cells are cleaved into small fragments and then incorporated into a protein complex, which binds to coding RNA. Once bound, the complex acts to silence protein synthesis by either degrading the coding RNA or preventing the protein

synthesising machinery from accessing the code.

Cellular vehicles

For siRNA to be used in clinical settings it is essential to encapsulate them in nanosized particles for efficient delivery. These nanoparticles act as vehicles that carry siRNAs to target cells where they can inhibit gene expression, and consequently, protein synthesis in the targeted cells. The efficiency of siRNA and these carriers have been demonstrated in

laboratories to varying degrees. Research is currently underway to develop efficient carriers in hopes of one day using siRNA to treat disease-causing cells, from genetic to acquired diseases such as Huntington’s or cancer.

For more information

Görgülü, A. 2016. Systemiska och cellulära begränsningar med in vivo RNAi behandling och utveckling av siRNA vektorer i terapeutiskt syfte.

_

Long dsRNAs are cut in cells into smaller fragments by enzymatic scissors called Dicers. These generated fragments are called small interfering RNA (siRNA) as they interfere and inhibit protein synthesis.

SiRNA is integrated into the RNA-induced silencing complex (RISC) which function to silence genes expression either by degradation or translational inhibition.

References

Related documents

It has been suggested that bone marrow cells express ribosomal proteins at different levels and that some ribosomal proteins have to be expressed in certain amounts to enable

The chosen approach to find a solution for this problem, is to create a framework which utilizes the so called genetic algorithm, which will tweak the different procedural

This article reports on the views of European experts and scholars who are members of the European COST Action CHIP ME IS1303 (Citizen’s Health through public-private

Hepatocytes derived from an OTCD patient were genetically edited ex vivo through a CRISPR-mediated dual gRNA approach and phenotypic restoration of urea cycle activity

The idea in all these systems was to evolve a population of candidate solutions to a given problem, using operators inspired by natural genetic variation and natural selection.. In

6 In order to apply for research infrastructure grants, this infrastructure should be included in the A1 thematic area “Infrastructure for research based on individual level

Conclusion: The findings of the study offer helpful insights into the concept of adherence to treatment and its components for health care providers, which can be used to develop

population of northern Sweden consists of genetically distinct sub-populations, and to study how this would affect the mapping of monogenic and complex genetic diseases.. Paper I